29/03/2019 11:15:00

Filing of Annual Report on Form 20-F

Summit Therapeutics plc 

(‘Summit’ or the ‘Company’)

Summit Therapeutics Files US Annual Report on Form 20-F

Oxford, UK, and Cambridge, MA, US, 29 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, provides notification that the Company has today filed its US Annual Report on Form 20-F for the year ended 31 January 2019 with the US Securities and Exchange Commission ("SEC").

The Form 20-F is available to download, either from the Investors section of the Company website at www.summitplc.com or from the SEC website at www.sec.gov.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit

 

 

Glyn Edwards / Richard Pye (UK office)

Tel:

44 (0)1235 443 951
Michelle Avery (US office)

 

+1 617 225 4455

 

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Tel:

+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson

 

 

 

 

 

N+1 Singer (Joint Broker)

Tel:

+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance

Tom Salvesen, Corporate Broking

 

 

 

 

 

Bryan Garnier & Co Limited (Joint Broker)

Tel:

+44 (0)20 7332 2500
Phil Walker / Dominic Wilson

 

 

 

MSL Group (US)

Tel:

+1 781 684 6557
Jon Siegal

 

summit@mslgroup.com

 

 

 

Consilium Strategic Communications (UK)

Tel:

+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson /

 

summit@consilium-comms.com

Lindsey Neville

 

 

-END-

Summit Master_rgb_png.png

Related content
12:00 - 
Result of AGM
18 Jun - 
Increased BARDA Award and Option Exercise
12 Jun - 
Summit Therapeutics Reports Financial Results and Opera..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Multiplying Good Recognizes Local Volunteers for Outstanding Public Service at 2019 Jefferson Awards in Washington, D.C.
2
Green Plains Prices Offering of $105 Million Aggregate Principal Amount of 4.00% Convertible Senior Notes due 2024
3
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Heron Therapeutics, Mammoth Energy, and ChinaCache and Encourages Investors to Contact the Firm
4
CLASS ACTION REMINDERS for FND, LTHM, PSMT, and AOS: Hagens Berman Reminds Investors of Class Actions on Behalf of Shareholders
5
CLASS ACTION REMINDERS for CLDR, TUSK and RMED: Hagens Berman Reminds Investors of Class Actions on Behalf of Shareholders

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 June 2019 12:50:51
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB7 - 2019-06-19 13:50:51 - 2019-06-19 12:50:51 - 1000 - Website: OKAY